{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:26:37Z","timestamp":1782487597554,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13085-0","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:06:32Z","timestamp":1773302792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing the non-inferiority of a 10-day compared with a 14-day vonoprazan\u2013amoxicillin dual therapy regimen for H. pylori eradication: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Azzam","family":"Zrineh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Akwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad M.","family":"Elsharkawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa Adel T.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeel","family":"Ayesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen Momtaz","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Karmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsayed S.","family":"Moubarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"13085_CR1","unstructured":"Parikh NS, Ahlawat R. Helicobacter Pylori. 2025."},{"key":"13085_CR2","doi-asserted-by":"crossref","unstructured":"Ansari S, Yamaoka Y. Survival of Helicobacter pylori in gastric acidic territory. Helicobacter. 2017;22(4).","DOI":"10.1111\/hel.12386"},{"issue":"1","key":"13085_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","volume":"9","author":"P Malfertheiner","year":"2023","unstructured":"Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9(1):19.","journal-title":"Nat Rev Dis Primers"},{"key":"13085_CR4","doi-asserted-by":"crossref","unstructured":"Ali A, AlHussaini KI. Helicobacter pylori: a contemporary perspective on pathogenesis, diagnosis and treatment strategies. Microorganisms. 2024;12(1).","DOI":"10.3390\/microorganisms12010222"},{"issue":"1","key":"13085_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3345\/cep.2019.01543","volume":"64","author":"JS Park","year":"2021","unstructured":"Park JS, Jun JS, Seo JH, Youn HS, Rhee KH. Changing prevalence of Helicobacter pylori infection in children and adolescents. Clin Exp Pediatr. 2021;64(1):21\u20135.","journal-title":"Clin Exp Pediatr"},{"issue":"11","key":"13085_CR6","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1136\/gutjnl-2025-336027","volume":"74","author":"JM Liou","year":"2025","unstructured":"Liou JM, Malfertheiner P, Hong TC, Cheng HC, Sugano K, Shah S, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei Global Consensus II. Gut. 2025;74(11):1767\u201391.","journal-title":"Gut"},{"issue":"12","key":"13085_CR7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1136\/gutjnl-2020-320839","volume":"69","author":"AC Ford","year":"2020","unstructured":"Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020;69(12):2113\u201321.","journal-title":"Gut"},{"issue":"3","key":"13085_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.5009\/gnl13451","volume":"9","author":"SS Chang","year":"2015","unstructured":"Chang SS, Hu HY. Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients. Gut Liver. 2015;9(3):346\u201352.","journal-title":"Gut Liver"},{"issue":"1","key":"13085_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report. Gut. 2017;66(1):6\u201330.","journal-title":"Gut"},{"issue":"9","key":"13085_CR10","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3748\/wjg.v30.i9.1213","volume":"30","author":"JE Kanu","year":"2024","unstructured":"Kanu JE, Soldera J. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis. World J Gastroenterol. 2024;30(9):1213\u201323.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"13085_CR11","first-page":"1215","volume":"12","author":"Z Zhong","year":"2022","unstructured":"Zhong Z, Zhan B, Xu B, Gao H. Emphasizing the importance of successful eradication of Helicobacter pylori on initial treatment. Am J Cancer Res. 2022;12(3):1215\u201321.","journal-title":"Am J Cancer Res"},{"issue":"7","key":"13085_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11894-016-0509-x","volume":"18","author":"EA Marcus","year":"2016","unstructured":"Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep. 2016;18(7):33.","journal-title":"Curr Gastroenterol Rep"},{"key":"13085_CR13","doi-asserted-by":"crossref","unstructured":"Kim SY, Chung JW. Best Helicobacter pylori eradication strategy in the era of antibiotic resistance. Antibiot (Basel). 2020;9(8).","DOI":"10.3390\/antibiotics9080436"},{"issue":"10","key":"13085_CR14","first-page":"1745","volume":"61","author":"M Darraj","year":"2025","unstructured":"Darraj M. Effectiveness of Classic Triple Therapy Compared with Alternative Regimens for Eradicating H. pylori: A Systematic Review. Med (B Aires). 2025;61(10):1745.","journal-title":"Med (B Aires)"},{"issue":"9","key":"13085_CR15","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","volume":"119","author":"WD Chey","year":"2024","unstructured":"Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024;119(9):1730\u201353.","journal-title":"Am J Gastroenterol"},{"key":"13085_CR16","doi-asserted-by":"crossref","unstructured":"Miftahussurur M, Pratama Putra B, Yamaoka Y. The potential benefits of vonoprazan as Helicobacter pylori infection therapy. Pharmaceuticals (Basel). 2020;13(10).","DOI":"10.3390\/ph13100276"},{"issue":"6","key":"13085_CR17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effects of vonoprazan 20\u00a0mg compared with esomeprazole 20\u00a0mg or rabeprazole 10\u00a0mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"13085_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11894-024-00939-3","volume":"26","author":"C Scarpignato","year":"2024","unstructured":"Scarpignato C, Hunt RH. Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. Curr Gastroenterol Rep. 2024;26(11):273\u201393.","journal-title":"Curr Gastroenterol Rep"},{"key":"13085_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","volume":"168","author":"N Inatomi","year":"2016","unstructured":"Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016;168:12\u201322.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"13085_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s40001-023-01249-6","volume":"28","author":"JH Feng","year":"2023","unstructured":"Feng JH, Cheng J, Lao YJ, Huang K, Mou JL, Hu F, et al. The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis. Eur J Med Res. 2023;28(1):272.","journal-title":"Eur J Med Res"},{"issue":"1","key":"13085_CR21","doi-asserted-by":"publisher","first-page":"e70009","DOI":"10.1111\/hel.70009","volume":"30","author":"YX Liu","year":"2025","unstructured":"Liu YX, Liu HN, Liu HQ, Yang YY, Cui HL, Fan LL, et al. Vonoprazan-Amoxicillin Dual Therapy Versus Drug Sensitivity-Based Individualized Therapy as a Rescue Regimen for Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial. Helicobacter. 2025;30(1):e70009.","journal-title":"Helicobacter"},{"issue":"1","key":"13085_CR22","doi-asserted-by":"publisher","first-page":"e13039","DOI":"10.1111\/hel.13039","volume":"29","author":"RC Du","year":"2024","unstructured":"Du RC, Hu YX, Ouyang Y, Ling LX, Xu JY, Sa R, et al. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis. Helicobacter. 2024;29(1):e13039.","journal-title":"Helicobacter"},{"issue":"10","key":"13085_CR23","first-page":"ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):ED000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"13085_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"key":"13085_CR25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"7109","key":"13085_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"11","key":"13085_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3345\/kjp.2012.55.11.403","volume":"55","author":"S Hahn","year":"2012","unstructured":"Hahn S. Understanding noninferiority trials. Korean J Pediatr. 2012;55(11):403.","journal-title":"Korean J Pediatr"},{"issue":"6","key":"13085_CR28","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.cgh.2024.01.022","volume":"22","author":"X Peng","year":"2024","unstructured":"Peng X, Yao JY, Ma YQ, Li GH, Chen HW, Wan Y, et al. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study. Clin Gastroenterol Hepatol. 2024;22(6):1210\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"41","key":"13085_CR29","doi-asserted-by":"publisher","first-page":"e35610","DOI":"10.1097\/MD.0000000000035610","volume":"102","author":"F Yang","year":"2023","unstructured":"Yang F, Yu B, Qin L, Dai X. A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori. Medicine. 2023;102(41):e35610.","journal-title":"Medicine"},{"key":"13085_CR30","doi-asserted-by":"publisher","first-page":"1543352","DOI":"10.3389\/fphar.2025.1543352","volume":"16","author":"Y Dong","year":"2025","unstructured":"Dong Y, Duan Z, Liu M, Ding Y, Chen G, Wang R, et al. Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication of Helicobacter pylori infection with vonoprazan amoxicillin: a prospective, multicenter, randomized controlled trial. Front Pharmacol. 2025;16:1543352.","journal-title":"Front Pharmacol"},{"issue":"3","key":"13085_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/cpdd.1357","volume":"13","author":"K Yan","year":"2024","unstructured":"Yan K, Dai X, Li Z, Rong W, Chen L, Diao X. Clinical Study on the Eradication of Helicobacter pylori by Vonoprazan Combined with Amoxicillin for 10-Day Dual Therapy. Clin Pharmacol Drug Dev. 2024;13(3):240\u20137.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"13085_CR32","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1111\/jgh.16761","volume":"39","author":"A Lin","year":"2024","unstructured":"Lin A, Lin Z, Liu Y, Chen S, Shao Y, Qiu F, et al. Ten-day versus 14-day vonoprazan-amoxicillin high-dose dual therapy for Helicobacter pylori eradication in China: A multicenter, open-label, randomized study. J Gastroenterol Hepatol. 2024;39(12):2645\u201353.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"13085_CR33","doi-asserted-by":"publisher","first-page":"e70070","DOI":"10.1111\/hel.70070","volume":"30","author":"Z Song","year":"2025","unstructured":"Song Z, Zuo X, Zhang Z, Wang X, Lin Y, Li Y, et al. Ten-Day Versus 14-Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial. Helicobacter. 2025;30(5):e70070.","journal-title":"Helicobacter"},{"issue":"27","key":"13085_CR34","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3748\/wjg.v30.i27.3304","volume":"30","author":"XP Huang","year":"2024","unstructured":"Huang XP, Liu YJ, Lin SW, Shao YF, Qiu F, Qiu QW, et al. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study. World J Gastroenterol. 2024;30(27):3304\u201313.","journal-title":"World J Gastroenterol"},{"key":"13085_CR35","doi-asserted-by":"crossref","unstructured":"Abadi ATB, Ierardi E. Vonoprazan and Helicobacter pylori treatment: a lesson from Japan or a limited geographic phenomenon? Front Pharmacol. 2019;10.","DOI":"10.3389\/fphar.2019.00316"},{"key":"13085_CR36","doi-asserted-by":"publisher","first-page":"9781212","DOI":"10.1155\/2019\/9781212","volume":"2019","author":"QJ Lyu","year":"2019","unstructured":"Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. Biomed Res Int. 2019;2019:9781212.","journal-title":"Biomed Res Int"},{"issue":"4","key":"13085_CR37","doi-asserted-by":"publisher","first-page":"e12495","DOI":"10.1111\/hel.12495","volume":"23","author":"M Li","year":"2018","unstructured":"Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, et al. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23(4):e12495.","journal-title":"Helicobacter"},{"issue":"2","key":"13085_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.04.012","volume":"161","author":"T Rokkas","year":"2021","unstructured":"Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, et al. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology. 2021;161(2):495\u2013e5074.","journal-title":"Gastroenterology"},{"issue":"6","key":"13085_CR39","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019\u201326.","journal-title":"Gut"},{"issue":"10","key":"13085_CR40","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00535-020-01709-4","volume":"55","author":"T Gotoda","year":"2020","unstructured":"Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-na\u00efve cohort of junior high school students in Japan. J Gastroenterol. 2020;55(10):969\u201376.","journal-title":"J Gastroenterol"},{"issue":"6","key":"13085_CR41","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1159\/000502287","volume":"101","author":"T Furuta","year":"2020","unstructured":"Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, et al. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori. Digestion. 2020;101(6):743\u201351.","journal-title":"Digestion"},{"issue":"6","key":"13085_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4103\/sjg.sjg_153_23","volume":"29","author":"BG Zhou","year":"2023","unstructured":"Zhou BG, Mei YZ, Jiang X, Zheng AJ, Ding YB. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials. Saudi J Gastroenterol. 2023;29(6):347\u201357.","journal-title":"Saudi J Gastroenterol"},{"issue":"3","key":"13085_CR43","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","volume":"163","author":"WD Chey","year":"2022","unstructured":"Chey WD, M\u00e9graud F, Laine L, L\u00f3pez LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology. 2022;163(3):608\u201319.","journal-title":"Gastroenterology"},{"key":"13085_CR44","doi-asserted-by":"crossref","unstructured":"Sugimoto M, Hira D, Murata M, Kawai T, Terada T. Effect of antibiotic susceptibility and CYP3A4\/5 and CYP2C19 genotype on the outcome of vonoprazan-containing Helicobacter pylori eradication therapy. Antibiot (Basel). 2020;9(10).","DOI":"10.3390\/antibiotics9100645"},{"issue":"3","key":"13085_CR45","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1124\/pr.112.007252","volume":"65","author":"JA Johnson","year":"2013","unstructured":"Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease\u2013implications for personalized medicine. Pharmacol Rev. 2013;65(3):987\u20131009.","journal-title":"Pharmacol Rev"},{"issue":"48","key":"13085_CR46","doi-asserted-by":"publisher","first-page":"13548","DOI":"10.3748\/wjg.v21.i48.13548","volume":"21","author":"Y Saito","year":"2015","unstructured":"Saito Y, Serizawa H, Kato Y, Nakano M, Nakamura M, Saito H, et al. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol. 2015;21(48):13548\u201354.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"13085_CR47","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636\u201348.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"13085_CR48","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/ctg.2015.18","volume":"6","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Nishimura A, Kennedy G, Hibberd M, Jenkins R, Okamoto H, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese\/non-Japanese Subjects. Clin Transl Gastroenterol. 2015;6(6):e94.","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"13085_CR49","doi-asserted-by":"publisher","first-page":"e12788","DOI":"10.1111\/hel.12788","volume":"26","author":"H Eto","year":"2021","unstructured":"Eto H, Suzuki S, Kusano C, Ikehara H, Ichijima R, Ito H, et al. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter. 2021;26(2):e12788.","journal-title":"Helicobacter"},{"issue":"3","key":"13085_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/87551225231166531","volume":"39","author":"E St Onge","year":"2023","unstructured":"St Onge E, Phillips B, Vonoprazan. A New Potassium-Competitive Acid Blocker. J Pharm Technol. 2023;39(3):139\u201346.","journal-title":"J Pharm Technol"},{"issue":"3","key":"13085_CR51","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5056\/jnm18029","volume":"24","author":"T Oshima","year":"2018","unstructured":"Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil. 2018;24(3):334\u201344.","journal-title":"J Neurogastroenterol Motil"},{"issue":"1","key":"13085_CR52","doi-asserted-by":"publisher","first-page":"103015","DOI":"10.1016\/j.jiph.2025.103015","volume":"19","author":"AA Semeya","year":"2026","unstructured":"Semeya AA, Abdel Hafez RSA, Al-Mihy NF, Elgamal R, Othman AAA. Vonoprazan-based triple therapy for Helicobacter pylori resistant to first-line regimens: A guideline-compliant 14-day multicenter study in Egypt. J Infect Public Health. 2026;19(1):103015.","journal-title":"J Infect Public Health"},{"issue":"9","key":"13085_CR53","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439\u201346.","journal-title":"Gut"},{"issue":"4","key":"13085_CR54","doi-asserted-by":"publisher","first-page":"e12692","DOI":"10.1111\/hel.12692","volume":"25","author":"CP Gao","year":"2020","unstructured":"Gao CP, Zhang D, Zhang T, Wang JX, Han SX, Graham DY, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter. 2020;25(4):e12692.","journal-title":"Helicobacter"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13085-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:03:33Z","timestamp":1776679413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13085-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13085"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13085-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Ethics approval for this systematic review and meta-analysis was not required as it involved the synthesis of already published data with no new human subject involvement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This is a systematic review and meta-analysis. No individual participant data are included, and all analyzed studies were already published and available in the public domain.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"788"}}